Back to search
FDAFDA · Food and drugs·Recall number D-264-2013

Suprax (cefixime for oral suspension) USP, 100 mg/5 mL, 50 mL bottles (when reconstituted), Manufactured for Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Baltimore, MD 21202, Manufactured by Lupin Limited Mumbai 400 058 India, NDC 68180-202-03.

Published April 24, 2013 · Recall initiated: January 31, 2013

Summary

FDA records drug Class III recall D-264-2013, published April 24, 2013 and initiated January 31, 2013. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 64,368 bottles; Lot: Lot #s: MSA 2021A, MSA 2024A, MSA 2025A, Exp July 2014. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Discoloration; Product may not meet specifications for color description once reconstituted.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Nationwide
Lot
Lot #s: MSA 2021A, MSA 2024A, MSA 2025A, Exp July 2014
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Suprax (cefixime for oral suspension) USP, 100 mg/5 mL, 50 mL bottles (when reconstituted), Manufactured for Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Baltimore, MD 21202, Manufactured by Lupin Limited Mumbai 400 058 India, NDC 68180-202-03. recalled?

Yes. FDA published recall D-264-2013 on April 24, 2013. Reported hazard: Discoloration; Product may not meet specifications for color description once reconstituted.

What should I do if I have this product?

Voluntary: Firm initiated · Letter